Browse

Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.

Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.

Glioblastoma is notoriously good at evading the immune system, making it particularly resistant to immunotherapy, but now researchers may have found a clever workaround. Scientists at the Universit…